

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



偉俊生物科技有限公司

Wai Chun Bio-Technology Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 660)

**(I) INSIDE INFORMATION;
(II) POSSIBLE DELAY IN PUBLICATION OF THE ANNUAL RESULTS
FOR THE YEAR ENDED 30 JUNE 2026; AND
(III) POSSIBLE SUSPENSION OF TRADING**

This announcement is made by the board of directors (the “**Board**”) of Wai Chun Bio-Technology Limited (the “**Company**”, together with its subsidiary, collectively referred to as (the “**Group**”)) pursuant to Rule 13.09(2)(a) and 13.49(3) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

POSSIBLE DELAY IN PUBLICATION OF THE 2026 ANNUAL RESULTS

The Board of the Company wishes to inform the shareholders of the Company (the “**Shareholders**”) that the Company is unable to publish the annual results for the year ended 30 June 2026 (the “**2026 Annual Results**”) on or before 30 September 2026 due to additional time is required by the Company and the auditor of the Company (the “**Auditor**”) to complete the audit process.

The Company is working closely with the Auditor to provide all requisite information and documents to complete the audit procedures as soon as possible. However, the expected date of the publication of the 2026 Annual Results will need to be further discussed and determined with the Auditor and will be announced as and when appropriate.

The Board hereby confirms that the Company is operating as usual and none of its business is affected.

Pursuant to Rule 13.49(1) of the Listing Rules, the Company is required to publish the 2026 Annual Results not later than three months after the end of the financial year (i.e. on or before 30 September 2026). In light of the aforementioned circumstance, it is expected that the Company is unable to publish the 2026 Annual Results on or before 30 September 2026, as required by the Listing Rules.

Pursuant to Rule 13.49(3) of the Listing Rules, if the Company is unable to publish the 2026 Annual Results within the prescribed timeframe, it must announce its results prepared based on the financial results which have yet to be agreed upon with the auditors (so far as such information is available). The Board, after due and careful consideration, is of the view that it would not be appropriate for the Company to publish its unaudited management accounts at this stage as they may not accurately reflect the financial performance and/or position of the Group and may be misleading to the investors and the Shareholders.

POSSIBLE SUSPENSION OF TRADING

Pursuant to Rule 13.50 of the Listing Rules, if the issuer fails to publish periodic financial information in accordance with the Listing Rules, the Stock Exchange of Hong Kong Limited will normally request suspension of trading in the issuer's securities and the suspension will normally continue until the issuer publishes an announcement containing the requisite financial information.

The Board will make further announcement(s) as and when appropriate to inform the Shareholders of any updates in respect of the publication of the 2026 Annual Results and the possible suspension of trading in the shares of the Company.

Shareholders and other investors are advised to exercise caution when dealing in the securities of the Company and, if in doubt, may seek professional advice from their own professional or financial advisors.

By order of the Board
Wai Chun Bio-Technology Limited
LAM KA CHUN
Chairman

Hong Kong, 22 September 2026

As at the date of this announcement, the Board consists of one executive director, namely Mr. Lam Ka Chun (Chairman and Chief Executive Officer), and three independent non-executive directors, namely Mr. Wong Po Keung, Ms. Xu Huiling and Mr. Wang Ziniu.